Aptus Pharma
APTUSPHARMALTD NSE
Aptus Pharma
Consumer GoodsNSE: APTUSPHARMALTD BSE: APPL Household Appliances
Key Fundamentals
SMEHousehold AppliancesConsumer GoodsMarket Cap
₹572 Cr
Volatility
High Risk
P/E Ratio
0
EBITDA
₹7.60 Cr
Return on Equity
19.79%
Debt to Equity
0.31
Book Value
₹13.61
52W High
₹341.7
52W Low
₹32.32
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 40.8%
Weaknesses
4- Stock is trading at 25.0 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 99.8 to 147 days.
- Working capital days have increased from 73.4 days to 117 days
Growth Rate
Revenue Growth
89.84% higher than
3Y
Net Income Growth
48.39% lower than
3Y
Cash Flow Change
-204% lower than
3Y
ROE
-55.53% lower than
3Y
ROCE
-37.54% lower than
3Y
EBITDA Margin (Avg.)
-18.85% lower than
3Y
Quarterly Results
| Particulars | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 9.76 | 14.8 | 14.38 | 32.2 |
| Expenses | 7.78 | 11.93 | 11.45 | 27.7 |
| Operating Profit | 1.98 | 2.87 | 2.93 | 4.5 |
| OPM % | 20.29% | 19.39% | 20.38% | 13.98% |
| Other Income | 0 | 0.08 | 0.01 | 0.12 |
| Interest | 0.11 | 0.36 | 0.43 | 0.35 |
| Depreciation | 0.11 | 0.15 | 0.16 | 0.25 |
| PBT | 1.76 | 2.44 | 2.35 | 4.02 |
| Tax % | 25.57% | 26.23% | 25.53% | 28.61% |
| Net Profit | 1.31 | 1.79 | 1.75 | 2.87 |
| EPS in Rs | 5.24 | 1.43 | 1.02 | 1.67 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 13.9 | 17.81 | 24.56 | 46.56 |
| Expenses | 13.28 | 16.27 | 19.71 | 39.11 |
| Operating Profit | 0.62 | 1.54 | 4.85 | 7.45 |
| OPM % | 4.46% | 8.65% | 19.75% | 16% |
| Other Income | 0 | 0.03 | 0.08 | 0.13 |
| Interest | 0.14 | 0.24 | 0.47 | 0.8 |
| Depreciation | 0.18 | 0.21 | 0.27 | 0.41 |
| PBT | 0.3 | 1.12 | 4.19 | 6.37 |
| Tax % | 33.33% | 28.57% | 26.01% | 27.47% |
| Net Profit | 0.19 | 0.8 | 3.1 | 4.62 |
| EPS in Rs | 2.38 | 10 | 2.48 | 2.69 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 0.3 | 0.3 | 5 | 6.86 |
| Reserves | 0.67 | 1.47 | 1.97 | 16.49 |
| Borrowings | 2.22 | 5.31 | 10.36 | 7.18 |
| Other Liabilities | 3.02 | 2.95 | 4.59 | 13.01 |
| Total Liabilities | 6.21 | 10.03 | 21.92 | 43.54 |
| Fixed Assets | 0.52 | 0.63 | 0.99 | 2.77 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 5.69 | 9.4 | 20.93 | 40.77 |
| Total Assets | 6.21 | 10.03 | 21.92 | 43.54 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | -0.18 | -2.17 | -1.84 | -5.6 |
| Investing | -0.35 | -0.3 | -0.54 | -6.37 |
| Financing | 0.81 | 2.86 | 6.68 | 7.79 |
| Net Cash Flow | 0.28 | 0.38 | 4.3 | -4.19 |
| Free Cash Flow | -0.53 | -2.5 | -2.46 | -7.79 |
| CFO/OP | -10 | -119 | -15 | -59 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 63.02 | 68.66 | 83.82 | 147 |
| Inventory Days | 176 | 184 | 285 | 232 |
| Days Payable | 104 | 72.25 | 52.89 | 139 |
| Cash Conversion Cycle | 135 | 180 | 316 | 239 |
| Working Capital Days | 51.99 | 67.02 | 36.41 | 117 |
| ROCE % | — | 26.48% | 38.18% | 29.96% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aptus Pharma insights
50 extracted metrics + investor summaries across FY22–FY26.
Documents
2
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
6 May - CARE report for half-year/year ended 31 March 2026 shows ₹13.02 crore IPO proceeds fully utilized, nil deviation. 6 May - CARE report for half-year/year ended 31 March 2026 shows ₹13.02 crore IPO proceeds fully utilized, nil deviation.
3
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - Aptus Pharma released FY26 results: revenue rose 89.59% to Rs 4,670.81 lakh, PAT up 49.05%. 28 Apr - Aptus Pharma released FY26 results: revenue rose 89.59% to Rs 4,670.81 lakh, PAT up 49.05%.
4
Statement Of Deviation(S) Or Variation(S) In Utilization Of Proceeds Of Initial Public Offer Pursuant To Regulation 32 Of SEBI (LODR) Regulations, 2015
28 Apr - Submitted IPO proceeds utilization statement for year ended 31 March 2026; no deviation or variation. 28 Apr - Submitted IPO proceeds utilization statement for year ended 31 March 2026; no deviation or variation.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - Aptus Pharma released FY26 results: revenue rose 89.59% to Rs 4,670.81 lakh, PAT up 49.05%. 28 Apr - Aptus Pharma released FY26 results: revenue rose 89.59% to Rs 4,670.81 lakh, PAT up 49.05%.
Frequently Asked Questions about Aptus Pharma
What does Aptus Pharma Ltd do?
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.[1]
Where is Aptus Pharma Ltd (544529) listed?
Aptus Pharma Ltd trades as APTUSPHARMALTD on the NSE and under code APPL on the BSE.
Which sector does Aptus Pharma Ltd belong to?
Aptus Pharma Ltd is classified under the Consumer Goods sector, in the Household Appliances industry.
What is the market capitalisation of Aptus Pharma Ltd?
Aptus Pharma Ltd has a market capitalisation of ₹571.5 Cr, which places it in the Small Cap band.
What is the PE ratio of Aptus Pharma Ltd?
Aptus Pharma Ltd trades at a PE ratio of 0.00, against a book value of ₹13.61 per share.
What is the 52-week high and low of Aptus Pharma Ltd?
Over the last 52 weeks Aptus Pharma Ltd has traded between ₹32.32 and ₹341.7.
What is the Return on Equity (ROE) of Aptus Pharma Ltd?
Aptus Pharma Ltd reported a return on equity of 19.79%. Its debt-to-equity ratio is 0.31.
Company Information
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544529.md for Aptus Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.